Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. A 52-week randomised, treat-to-target, placebo-controlled, double-blinded, parallel-group, multinational, multi-centre trial

Next Previous
X
Search
Trial Profile

The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. A 52-week randomised, treat-to-target, placebo-controlled, double-blinded, parallel-group, multinational, multi-centre trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liraglutide (Primary) ; Insulin
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms ADJUNCT-ONE
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 01 Dec 2021 Results of post-hoc analysis of two studies (ADJUNCT ONE and ADJUNCT TWO) assessing 26 weeks of liraglutide treatment in type 1 diabetes (T1D), published in the Diabetes, Obesity and Metabolism.
    • 29 Jun 2021 Results of randomized controlled phase 3 trials (ADJUNCT ONE (NCT01836523) and TWO (NCT02098395)), presented at the 81st Annual Scientific Sessions of the American Diabetes Association
    • 20 Dec 2016 Primary endpoint (Change from baseline in body weight) has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top